ViGeneron
Latest round
- Series A
Last raised
- Nov 2019
Total raised
- Undisclosed
Investors
- 2
About ViGeneron
ViGeneron GmbH is a biotechnology company focused on advancing gene therapies for treating ophthalmic diseases.ViGeneron GmbH, founded in 2017 and headquartered in Munich, Germany, specializes in gene therapy solutions for ophthalmic conditions. The company was founded by Stylianos Michalakis, who has a background in the biotechnology sector.ViGeneron GmbH specializes in developing advanced gene therapies aimed at treating ophthalmic diseases, particularly those with significant unmet medical needs. The company has established three proprietary adeno-associated virus (AAV) technology platforms: the vgAAV vector platform, the vgRNA REVeRT vector platform, and the transactivation platform. The vgAAV platform enhances transduction efficiency, allowing for less invasive intravitreal treatments, thereby broadening its applicability across various retinal cell types. The vgRNA REVeRT platform addresses the challenge of large gene mutations by utilizing a unique vector approach that facilitates mRNA trans-splicing, while the transactivation platform offers the capability to modulate the expression of multiple genes simultaneously. These innovative therapies target ophthalmic diseases such as inherited retinal disorders, with potential applications in other medical fields, including neuroscience and cardiovascular diseases.ViGeneron GmbH operates on a model that integrates partnerships with leading biopharmaceutical companies to expedite the development and commercialization of its gene therapy solutions. Revenue generation is driven through strategic collaborations and partnerships, where the firm engages in B2B transactions, providing its proprietary gene therapy technologies to industry partners involved in drug development. This model includes upfront payments, milestone payments linked to the achievement of specific development goals, and royalty agreements based on future sales of products that utilize ViGeneron’s technology.ViGeneron GmbH plans to continue developing its innovative gene therapy solutions, aiming to launch new products targeting various ophthalmic conditions in the near future. The company is focused on expanding its market reach into additional regions across Europe and North America, with specific timelines yet to be disclosed.
Who invested in ViGeneron
2 investors across 1 round
See all investors in ViGeneron
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 28, 2019
Amount
Undisclosed
Investors
Questions about ViGeneron
Who invested in ViGeneron?
ViGeneron has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ViGeneron raised?
ViGeneron has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ViGeneron last raise money?
ViGeneron's most recent round on record is a Series A, in Nov 2019.
What does ViGeneron do?
ViGeneron GmbH is a biotechnology company focused on advancing gene therapies for treating ophthalmic diseases.
Where is ViGeneron headquartered?
ViGeneron is headquartered in Munich, Germany.
Which VCs invest in companies like ViGeneron?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at ViGeneron's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ViGeneron? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.